Q2 was very good for Biosyent (RX)

The company delivered great results in Q2, with 29% sequential pharma revenue growth, 60% year-over-year pharma revenue growth and 62% year-over-year pre-tax eps growth. Much more to come, I would think, because all of their meds are either in the approval phase, launch phase or growth phase. This was the 15th consecutive quarter of pharma revenue growth for RX.

I highly recommend investors watch the Q2 presentation on the company's website. Some interesting tidbits of contained therein...

- Made first (modest) shipment of FeraMAX 150 outside of Canada.

- Are in discussions with potential partners for FeraMAX 150 + FeraMAX powder outside of Canada.

- Cathejell was adopted by some additional regional health authorities and hospitals